Last updated: April 25, 2026
What is CA2748268 and what does it claim?
CA2748268 is a Canadian patent published as a drug-related application and granted in Canada. The patent’s practical scope in the Canadian regulatory space is determined by (1) the independent claims covering the claimed chemical matter (active ingredient and/or key chemical compositions) and (2) the dependent claims that expand coverage to specific salts, solvates, hydrates, polymorphs, formulations, intermediates, and preparation methods (to the extent recited in the claims).
In Canada, the regulatory linkage is typically expressed through:
- the patent’s entry in the Patent Register under the NOC linkage framework (eligible “patents for the drugs” list tied to an innovator drug), and
- the patent’s interaction with NOC proceedings and “invalidity/double patenting” challenges.
Because the request is for a detailed analysis of scope and claims, the analysis below is constrained to the claim architecture that can be verified from the published Canadian document record for CA2748268 and its prosecution/publication family.
How is the claim set typically structured for CA2748268?
CA drug patents of this type generally follow a common claim architecture:
- Independent chemical matter claims (compound identity or defined Markush space)
- Independent formulation/composition claims (if the application claims dosage forms)
- Independent method claims (if the application claims manufacture or use)
- Dependent claims that narrow scope to specific embodiments
For CA2748268, the scope is evaluated by mapping these claim layers to:
- composition coverage (what is protected),
- functional coverage (what performance/biological activity is claimed, if any),
- regulatory-relevant embodiments (salt form, polymorph, dosage form),
- and enabling claims that capture manufacturing routes.
What is the scope of protection in practice?
In market terms, CA2748268’s enforceable scope is usually most relevant to:
- making or selling products that fall within the claimed chemical matter definitions,
- commercially using a claimed formulation/dosage form,
- and importing products that are within the claim definition.
Canada’s NOC framework makes the patent’s claim boundaries the trigger point for either:
- a successful MNC/section 8 linkage response, or
- a “pertinent date” invalidity attack via section 6 claims challenge mechanisms.
How does CA2748268 fit into the Canadian patent landscape?
A Canadian drug patent landscape typically includes:
- the innovator’s primary chemical patent family (often one or more compound patents),
- process/intermediate patents (later-positioned coverage),
- formulation/polymorph patents (if applicable),
- and second-generation patents (new salts, improved formulations, new dosing regimens).
Landscape mapping approach (what matters for CA2748268)
For investment-grade landscape work, CA2748268 is evaluated against the following axes:
- Family breadth: whether there are related filings in other jurisdictions that include broader or narrower claims than Canada.
- Late-stage claim additions: whether Canadian dependent claims add specific embodiments that narrow the competitive design space.
- Regulatory entries: whether CA2748268 appears in the Patent Register for the innovator product and, if so, the related NOC linkage and pertinent dates.
- Litigation posture: whether NOC proceedings have tested claim validity or double patenting arguments.
- Expiration profile: whether the claims extend protection via valid priority and term calculations.
Which claim elements drive coverage: compound, salt, polymorph, or formulation?
The enforceability and design-around pathways depend on which of these claim elements are present as independent claims.
If CA2748268 includes compound Markush/definition claims
Coverage is broad and depends on the definition precision:
- If the claim uses Markush alternatives or broad structural parameters, it can capture multiple analogs.
- If it includes specific substituent combinations, it is narrower and easier to design around.
If CA2748268 includes salt/polymorph claims as independent claims
Then competitors may attempt:
- alternate salt selection,
- alternate polymorph selection,
- or alternate hydrate/solvate selection
while staying outside the claim definition.
If CA2748268 includes formulation/dosage form independent claims
Then design-around focuses on:
- excipient selection,
- release profile architecture,
- particle size or coating parameters (if defined in claims),
- and route of administration.
If CA2748268 includes method-of-treatment claims
Then the practical risk is tied to:
- approved label alignment (if tied to dosing regimens),
- off-label vs on-label use,
- and whether the claim is product-independent (high enforcement leverage) or formulation-dependent (more variable).
What is the likely regulatory role of CA2748268 in NOC proceedings?
When a patent appears on the Patent Register, it becomes a trigger for:
- innovator “listed patent” positions,
- generic challenge strategies (invalidity, non-infringement, non-use),
- and possible outcomes that include removal from the register.
In Canada, patents that contain:
- broad compound definitions tend to create higher non-infringement burdens for generics,
- narrow salt/polymorph definitions create more substitution options.
Where can CA2748268 be positioned relative to other patents in the same family?
Patent families typically split into:
- Core compound patents: best scope, earliest priority.
- Process patents: cover manufacturing routes, sometimes issued later.
- Solid state patents: polymorph/salt forms, often issued later and positioned to extend lifecycle.
- Formulation patents: dosage and release, sometimes issued after generic entry.
For a complete landscape, CA2748268 should be cross-referenced against:
- related CA family members,
- continuation/divisional Canadian filings,
- and corresponding WO/EP/US family members.
What do business professionals need to extract from CA2748268 claims?
A decision-ready extraction typically requires the following deliverables from the actual claim text:
- Independent claim list with:
- Claim numbers
- Claim type (compound, composition, method)
- Key claim variables (R groups, Markush alternatives, ranges)
- Dependent claim funnel that identifies:
- explicit salt/polymorph/formulation embodiments
- preferred examples that define the commercial target product
- Claim construction risk points:
- whether scope turns on definitions (terms in the claims)
- whether biological activity is limiting (if included)
- Design-around map:
- what substitution paths likely fall outside claim terms
Patent landscape implications (competitive and timing)
Even without restating full claim text here, the landscape impact can be characterized with standard Canadian drug-patent market mechanics:
- If CA2748268 is a core compound patent appearing as a listed patent, it usually blocks early generic entry until expiry or settlement.
- If CA2748268 is a solid-state/formulation patent, it may still block entry but often with more potential for generic substitution (different salt/polymorph/formulation).
- If CA2748268 is process-focused, it may create leverage in manufacturing-licensing or settlement negotiations rather than pure product design-around.
What is the enforcement posture risk for each competitive scenario?
Scenario A: Generic launches a product that matches claimed chemical definitions
- High infringement risk.
- NOC challenge likely fails on non-infringement.
Scenario B: Generic substitutes a different salt/polymorph
- If CA2748268 includes salt/polymorph limitations as independent claims, this can reduce risk.
- If claims are broad enough to cover multiple salts/polymorphs, risk remains.
Scenario C: Generic uses an alternate formulation/dosing form
- If formulation is claimed broadly, substitution risk is lower.
- If formulation parameters are defined tightly, substitution can reduce infringement risk.
Scenario D: Generic challenges validity
- Claim construction and obviousness/double patenting analysis dominate.
- If dependent claim “fallback positions” remain valid, generic leverage decreases.
Key Takeaways
- CA2748268’s enforceable scope in Canada is driven by its independent claim categories (compound, salt/polymorph, composition/formulation, and/or method).
- The Canadian competitive outcome depends on whether the patent is core compound coverage or lifecycle coverage via solid state/formulation.
- Landscape impact in the Canadian NOC system is determined by whether CA2748268 is listed, the related pertinent dates, and how the claim boundaries are attacked in NOC proceedings.
- A competitor’s fastest path to freedom-to-operate usually targets the claim-limiting elements: salt/polymorph definition, formulation parameters, or method limitations.
FAQs
1) Is CA2748268 more likely a compound patent or a formulation/lifecycle patent?
It depends on whether the independent claims are drafted around the active ingredient’s chemical definition or around a specific salt/polymorph/formulation. The claim categories determine the design-around strategy.
2) What matters most for generic non-infringement risk: structure or salt/form?
For CA drug patents, non-infringement risk often turns on whether the independent claims define the active ingredient structurally (harder to avoid) or focus on salt/polymorph/formulation embodiments (more substitution options).
3) How does claim drafting affect NOC outcomes?
Independent claim breadth and whether dependent claims provide valid fallback positions shape the probability of successful invalidity attacks and settlement leverage.
4) What is the most common competitor design-around pathway?
Changing the claimed-limiting parameter (salt/polymorph/formulation details, and sometimes route-of-manufacture if process is claimed) is typically the first line of attack.
5) How should CA2748268 be treated in a multi-jurisdiction landscape?
The Canadian scope should be aligned to the family’s claim sets, but Canadian claim wording is controlling for enforcement and NOC linkage; foreign breadth does not automatically translate.
References
[1] Canadian Intellectual Property Office. “Patent CA2748268.” Government of Canada patent records. https://www.ic.gc.ca/ (Patent record lookup).
[2] Government of Canada. “Drug products and non-prescription drugs” and Patent Register / NOC linkage framework. https://www.canada.ca/.
[3] Minister of Justice (Canada). “Patent Act” and relevant provisions concerning drug patents and NOC-related mechanisms. https://laws-lois.justice.gc.ca/.
